Figure 1.

Dihydromyricetin protected against cisplatin-induced general toxicity and nephrotoxicity in vivo. (a and b) BUN and SCr measurement. (c) Periodic acid-Schiff (PAS) staining. Kidney sections from the cisplatin-treated group showed severe cast formation and severe tubular injury. Cisplatin with DMY (500 mg/kg) showed less tubular destruction and mild casts (indicated with arrows). Data are presented as mean ± SD. ^∗∗ P < 0.01 versus cisplatin treatment group, ^∗ P < 0.05 versus cisplatin treatment group, and ^## P < 0.01 versus nondrug treatment group.